Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
In mid-December, five Wichita, Kan, patients with newly diagnosed diabetes became the first humans to be treated with a substance produced by recombinant DNA technology. The five began therapy with insulin produced by bacteria into which the human insulin gene had been introduced. The recombinant insulin (also known as biosynthetic insulin), which is being produced by Eli Lilly and Co, had previously been administered to healthy human volunteers in the United States, Great Britain, Greece, and West Germany and found to be free of toxic effects. Phase II testing of the substance is now being carried out under the supervision of Richard Guthrie, MD, professor and chairman of the Department of Pediatrics at the University of Kansas School of Medicine in Wichita; Arthur Krosnick, MD, of the Mercer Medical Center in Trenton, NJ; and Frederick Whitehouse, MD, a former president of the American Diabetes Association who is with the Henry
JAMA – American Medical Association
Published: Jan 23, 1981
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.